Market Place
Sourcing Support
Bioinvent To Showcase BI-1808 And Keytruda In Ovarian Cancer
21 Apr 2026 //
PHARMIWEB
BioInvent International AB Publishes Annual Report 2025
31 Mar 2026 //
PHARMIWEB
Bioinvent Achieves Phase 3 Milestone For HMI-115 In Endometriosis
26 Mar 2026 //
PHARMIWEB
BioInvent AB: Year-End Report January 1 - December 31, 2025
26 Feb 2026 //
ACCESSWIRE
Bioinvent Nominates Two New Board Members for 2026 AGM
23 Feb 2026 //
PHARMIWEB
Bioinvent Reveals Positive Phase 2A Results For BI-1808
05 Jan 2026 //
PHARMIWEB
BioInvent To Participate In Upcoming Investor Conference
18 Dec 2025 //
PHARMIWEB
Bioinvent Unveils Strong Phase 2A Data For BI-1206, Combo In NHL
08 Dec 2025 //
PHARMIWEB
Bioinvent Unveils Positive Phase 2A BI-1808 Monotherapy Results
07 Dec 2025 //
PHARMIWEB
BioInvent`s BI-1607: Preclinical, Phase 1 Data in HER2+ Tumors
18 Nov 2025 //
PHARMIWEB
BioInvent BI-1910 Ph1 Data Validates TNFR2 In Solid Tumors
07 Nov 2025 //
PHARMIWEB
Bioinvent Presents Ph 2a Data For BI-1206 Combo In r/r NHL
03 Nov 2025 //
PHARMIWEB
Bioinvent to Unveil Phase 2 a Bi-1808 Monotherapy Data in CTCL
03 Nov 2025 //
PHARMIWEB
Transgene & BioInvent’s BT-001 Shows Strong Antitumor Activity
20 Oct 2025 //
ACCESSWIRE
Transgene, Bioinvent To Unveil BT-001, Oncolytic Virus Data
13 Oct 2025 //
ACCESSWIRE
Bioinvent Starts BI-1206 Ph 2a Trial In Advanced NSCLC & Melanoma
08 Oct 2025 //
PR NEWSWIRE
Bioinvent To Unveil BI-1910, Ph1 Data For Solid Tumors At SITC
03 Oct 2025 //
ACCESSWIRE
BioInvent Announces Board of Directors Update
02 Sep 2025 //
PHARMAWEB
BioInvent International AB: Interim Report January - June 2025
26 Aug 2025 //
ACCESSWIRE
BioInvent Restructures Portfolio to Boost Lead Clinical Programs
26 Aug 2025 //
ACCESSWIRE
Transgene, BioInvent to Share BT-001 Oncolytic Virus Data at ESMO
28 Jul 2025 //
ACCESSWIRE
BioInvent Presents Phase 2a Data for BI-1808 in CTCL at EHA 2025
12 Jun 2025 //
ACCESSWIRE
BioInvent Posts Positive Ph1 Results for Bi-1206 With Keytruda
11 Jun 2025 //
ACCESSWIRE
BioInvent Highlights BI-1910 Clinical Data at PAGE 2025
04 Jun 2025 //
ACCESSWIRE
XOMA buys Mezagitamab rights from BioInvent for up to $30M
27 May 2025 //
GLOBENEWSWIRE
BioInvent updates Phase 2a data for BI-1206 combo in Lymphoma
14 May 2025 //
ACCESSWIRE
BioInvent Presents CTCL Phase 2a Data for BI-1808 at EHA 2025
14 May 2025 //
ACCESSWIRE
BioInvent to Participate in Upcoming Investor Conferences
05 May 2025 //
#N/A
BioInvent International AB: Interim Report January - March 2025
29 Apr 2025 //
ACCESSWIRE
BioInvent gets FDA Fast Track for BI-1808 in T-cell Lymphoma
29 Apr 2025 //
ACCESSWIRE
BioInvent gets payment as Takeda advances mezagitamab to Phase 3
08 Apr 2025 //
ACCESSWIRE
BioInvent International AB Publishes Annual Report 2024
03 Apr 2025 //
ACCESSWIRE
BioInvent to Participate in Upcoming Investor Conferences
01 Apr 2025 //
ACCESSWIRE
BioInvent International AB: 2024 Year-End Report
27 Feb 2025 //
ACCESSWIRE
Transgene & BioInvent - First Patient Treated in Phase I Trial Assessing BT-001
10 Oct 2023 //
BUSINESSWIRE
